Ianalumab in Sjögren's syndrome: what can we learn from lupus trials? - Authors' reply
- PMID: 36088946
- DOI: 10.1016/S0140-6736(22)01538-0
Ianalumab in Sjögren's syndrome: what can we learn from lupus trials? - Authors' reply
Comment on
-
Ianalumab in Sjögren's syndrome: what can we learn from lupus trials?Lancet. 2022 Sep 10;400(10355):807-808. doi: 10.1016/S0140-6736(22)01536-7. Lancet. 2022. PMID: 36088945 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical